Search clinical trials for: HCP0912 / Irbesartan and Atorvastatin

Total 1071 results

Hanmi Pharmaceutical Company Limited

Completed

Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

Hypertension | Hyperlipidemia

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin

Healthy

Korea, Republic of
Technische Universität Dresden

Completed

Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.

Healthy Subjects

Germany
Sanofi

Completed

Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension

Type 2 Diabetes Mellitus

Korea, Republic of
Mario Negri Institute for Pharmacological Research

Active, not recruiting

Remission Clinic in Proteinuric Chronic Nephropathies

Chronic Kidney Disease

Italy
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects

Therapeutic Equivalency

China
Hotel Dieu de France Hospital
Pfizer; Nouvelle Société Française d'Athérosclérose

Completed

The HDL Particle Protection Study (HDL PROTECT)

Dyslipidemia in Patients With Diabetes Mellitus

Lebanon
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension

Hypertension

United States, Belgium, Canada, Germany, Russian Federation, France, Israel, Netherlands
Sanofi

Completed

Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy

Hypertension

Russian Federation
Sanofi
Bristol-Myers Squibb

Completed

The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension

Hypertension

United States
Steno Diabetes Center Copenhagen

Completed

Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria

Type 2 Diabetes | Microalbuminuria

Denmark
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Pfizer

Completed

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

HIV-1 Infection

United States, Puerto Rico
Steno Diabetes Center Copenhagen
Bristol-Myers Squibb; Sanofi-Synthelabo

Completed

Irbesartan in Type 2 Diabetes

Hypertension | Type 2 Diabetes | Microalbuminuria
Hanmi Pharmaceutical Company Limited

Completed

Investigating the Pharmacokinetic Characteristics of HIP1402 in Healthy Male Volunteers

Healthy
Astellas Pharma Inc

Completed

Special Drug Use-Results Survey of Lipitor Tablets (ALWAYS)

Hypercholesterolemia

Japan
University of Southern Denmark
Bristol-Myers Squibb

Completed

Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)

Myocardial Infarction

Denmark
Zhi-Hong Liu, M.D.

Terminated

A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy

Obesity and Glomerulopathy

China
The Affiliated Hospital of Qingdao University

Recruiting

A Bioequivalence Trial of Irbesartan Tablets（0.15g） in Healthy Chinese Subjects

Bioequivalence | Irbesartan Tablets (0.15g/Tablet) | Under Fasted Condition | Under Fed Condition

China
Technische Universität Dresden

Completed

Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.

Healthy Subjects

Germany
Sanofi
Bristol-Myers Squibb

Completed

I PREVENT - Irbesartan In Hypertensive Diabetic Patients

Hypertension

Egypt
Sanofi
Bristol-Myers Squibb

Completed

I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients

Hypertension

Egypt
Travere Therapeutics, Inc.

Active, not recruiting

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)

Immunoglobulin A Nephropathy

United States, Australia, Belgium, Croatia, Czechia, Estonia, France, Germany, Hong Kong, Italy, Korea, Republic of, Lithuania, New Zealand, Poland, Portugal, Spain, Taiwan, United Kingdom
Sanofi
Bristol-Myers Squibb

Completed

I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy

Hypertension

Egypt
Jiangsu Famous Medical Technology Co., Ltd.

Unknown

Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease

Diabetic Kidney Disease

China
Clinical Research Management, Inc.
Duke University; Bill and Melinda Gates Foundation; Syneos Health; University of... and other collaborators

Unknown

Multiple Treatments for Ebola Virus Disease (EVD)

Ebola Virus Disease
Damanhour University

Completed

Drug Interaction Between Irbesartan and Hydrochlorothiazide

Healthy

Egypt
Ligand Pharmaceuticals

Completed

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

Hypertension

United States
Hospital de Clinicas de Porto Alegre

Unknown

Statin for Immunomudulation in Sepsis

Sepsis

Brazil
Travere Therapeutics, Inc.

Active, not recruiting

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (DUPLEX)

Focal Segmental Glomerulosclerosis

United States, Australia, Belgium, Croatia, Estonia, Germany, Hong Kong, Italy, Korea, Republic of, Poland, Portugal, Spain, Taiwan, United Kingdom, Argentina, Brazil, Canada, Czechia, Denmark, France, New Zealand, Sweden
Novartis

Completed

VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis

Hypertension

Switzerland, Germany
Sanofi
Bristol-Myers Squibb

Completed

AMISH : Aprovel for Management of Isolated Systolic Hypertension

Hypertension

Korea, Republic of, Mexico, Taiwan, Thailand, Philippines, Chile, China, Indonesia
Sanofi

Completed

Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population

Hypertension

China
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension

Hypertension

United States, Canada, Germany, Russian Federation, France
GlaxoSmithKline

Completed

A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
Sanofi

Completed

Irbesartan and Amlodipine Combination in Controlling Blood Pressure (I-COMBO)

Hypertension

India, Philippines, Taiwan, Korea, Republic of
Sanofi

Completed

Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy (I-ADD)

Hypertension

Morocco, Brazil, Colombia, Guatemala, Mexico, Tunisia, United Arab Emirates, Venezuela
University of Magdeburg
Sanofi

Unknown

Irbesartan and Adhesion Molecules in AF (CREATIVE-AF)

Persistent Atrial Fibrillation

Germany
Assistance Publique - Hôpitaux de Paris

Recruiting

Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU. (START-or-NOT)

Acute Kidney Injury

France
Handok Inc.

Completed

Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Handok Inc.

Completed

Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

Essential Hypertension

Korea, Republic of
Alnylam Pharmaceuticals

Completed

A Study to Evaluate ALN-AGT01 in Patients With Hypertension

Hypertension

United Kingdom
Montefiore Medical Center
NCM USA

Completed

Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

Neuroendocrine Tumors
Obafemi Awolowo University Teaching Hospital
Open Philanthropy

Recruiting

ATORvastatin in Pulmonary TUBerculosis (ATORTUB)

Tuberculosis | Pulmonary Tuberculosis | Koch's Disease

Nigeria
Organon and Co

Completed

A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)

Hyperlipidemia
Zhejiang Hisun Pharmaceutical Co. Ltd.

Unknown

Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia (HS-25-C-01)

Primary Hypercholesterolemia
Hippocration General Hospital

Completed

Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients

Coronary Artery Disease | Atherosclerosis | Endothelial Dysfunction | Oxidative Stress | HMG-CoA Reductase Inhibitor Toxicity

Greece
Tanta University

Completed

Statin Impact on Hepatic Decompensation

Quality of Life

Egypt
Università degli Studi dell'Insubria

Unknown

Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan

Diastolic Function | Left Atrial Volume | Renin Angiotensin System | Hypertensive Heart Disease | Antihypertensive Drugs

Italy
Makerere University
University of Oxford; Case Western Reserve University

Unknown

Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial (STAR)

HIV Infection
Organon and Co

Completed

An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)

Hypercholesterolemia

Search clinical trials for: HCP0912 / Irbesartan and Atorvastatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations